Form 4: Fractyl Health Director Ajay Royan Receives Stock Options

Director Ajay Royan was granted 22,500 stock options as part of Fractyl Health's non-employee director compensation policy.

Summary

• Director Ajay Royan received a grant of 22,500 stock options on June 10, 2026.
• The options have an exercise price of $0.7318 per share.
• The grant is part of the standard compensation package for non-employee directors at Fractyl Health.
• The options are set to expire on June 9, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that carries no significant signal regarding company performance or outlook.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Minor dilution of existing shareholders upon the potential future exercise of these options.

Risks

• Vesting is contingent upon continued service on the board of directors.
• The value of the options is subject to market volatility and the future performance of GUTS stock.

Future Outlook

The options vest in a single installment on the earlier of the next annual meeting of stockholders or the first anniversary of the grant, provided the director remains in service.

Industry Context

StockSavvy.ai notes that equity grants for non-employee directors are a standard corporate governance practice in the biotechnology sector to ensure board members are incentivized to oversee long-term strategic growth.

Comparison to Industry Standards

• The grant follows standard industry practices for non-employee director compensation in small-cap biotech firms.
• The vesting schedule is consistent with typical one-year cliff vesting structures used by peer companies.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders due to the small size of the grant relative to total outstanding shares.

Next Steps

• Vesting of options on the earlier of the next annual meeting or June 10, 2027.

Key Dates

Keywords

Fractyl Health, GUTS, Director Compensation, Stock Options, Insider Transaction, Form 4